Back to search results

A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Abroad (travel likely)RecruitingPHASE2

Conditions

GM2 Gangliosidosis · Niemann-Pick Type C Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Associação Hospitalar de Prot à Infância Dr. Raul Carneiro, Água Verde, Curitiba, Brazil

    Contact: Study coordinator (Daniel Almeida do Valle) · daniel.valle@hpp.org.br · +55 (41) 2108-3861 - option 3
    Contact: Principal Investigator (Daniel Almeida do Valle)

  • Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil

    Contact: Study coordinator (Roberta Souto) · rsouto@hcpa.edu.br · +55 51 9985-0919
    Contact: Principal Investigator (Roberto Giugliani, Prof. Dr.)

  • Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Rio de Janeiro, Brazil

    Contact: Study coordinator (Dafne Horovitz) · dafne.horovitz@fiocruz.br · +55 21 2554-1709
    Contact: Principal Investigator (Dafne Horovitz)
View source on ClinicalTrials.gov(opens in a new tab)